Towards Gene- and Gender-based Risk Estimates in Lynch Syndrome; Age-specific Incidences for 13 Extra-colorectal Cancer Types

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 Oct 25

PMID 29065108

Citations 16

Authors

Christina Therkildsen

Steen Ladelund

Lars Smith-Hansen

Lars Joachim Lindberg

Mef Nilbert

Affiliations

Soon will be listed here.

Abstract

Background: In Lynch syndrome, inherited mismatch repair (MMR) defects predispose to colorectal cancer and to a wide spectrum of extra-colorectal tumours. Utilising a cohort study design, we aimed to determine the risk of extra-colorectal cancer and to identify yet unrecognised tumour types.

Methods: Data from 1624 Lynch syndrome mutation carriers in the Danish hereditary non-polyposis colorectal cancer register were used to estimate the sex- and age-specific incidence rate ratios (IRRs) for 30 extra-colorectal malignancies with comparison to the general population.

Results: Significantly increased IRRs were identified for 13 cancer types with differences related to gender, age and disease-predisposing gene. The different cancer types showed variable peak age incidence rates (IRs) with the highest IRs for ovarian cancer at age 30-49 years, for endometrial cancer, breast cancer, renal cell cancer and brain tumours at age 50-69 years, and for urothelial cancer, small bowel cancer, gastric cancer, pancreatic cancer and skin tumours after age 70.

Conclusions: The broad spectrum of tumour types that develop at an increased incidence defines Lynch syndrome as a multi-tumour syndrome. The variable incidences in relation to age, gender and gene suggest a need for individualised surveillance.

Citing Articles

Genomic Medicine in the Developing World: Cancer Spectrum, Cumulative Risk and Survival Outcomes for Lynch Syndrome Variant Heterozygotes with Germline Pathogenic Variants in the and Genes.

Ndou L, Chambuso R, Algar U, Boutall A, Goldberg P, Ramesar R Biomedicines. 2025; 12(12.

PMID: 39767815 PMC: 11672899. DOI: 10.3390/biomedicines12122906.

An Unusual Presentation of Synchronous Breast Cancer and Skin Malignancy in a Patient with Lynch Syndrome: A Case Report and Review of the Literature.

Elghobashy M, Siafakas M, Elshafie M, Hejmadi R, Basu N, Shaaban A Biomedicines. 2024; 12(6).

PMID: 38927449 PMC: 11201021. DOI: 10.3390/biomedicines12061242.

Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer.

Hodan R, Rodgers-Fouche L, Chittenden A, Dominguez-Valentin M, Ferriss J, Gima L Fam Cancer. 2023; 22(4):437-448.

PMID: 37341816 DOI: 10.1007/s10689-023-00341-4.

Hereditary cancer syndromes.

Imyanitov E, Kuligina E, Sokolenko A, Suspitsin E, Yanus G, Iyevleva A World J Clin Oncol. 2023; 14(2):40-68.

PMID: 36908677 PMC: 9993141. DOI: 10.5306/wjco.v14.i2.40.

Metastatic Renal Cell Carcinoma to the Cerebrum in a Patient With Lynch Syndrome: A Case Report.

Hrushka J, Allison R Cureus. 2021; 13(5):e14804.

PMID: 34094760 PMC: 8168914. DOI: 10.7759/cureus.14804.

References

Harkness E, Barrow E, Newton K, Green K, Clancy T, Lalloo F . Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. J Med Genet. 2015; 52(8):553-6. DOI: 10.1136/jmedgenet-2015-103216. View

Plaschke J, Engel C, Kruger S, Holinski-Feder E, Pagenstecher C, Mangold E . Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol. 2004; 22(22):4486-94. DOI: 10.1200/JCO.2004.02.033. View

Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond V . Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009; 302(16):1790-5. PMC: 4091624. DOI: 10.1001/jama.2009.1529. View

Syngal S, Brand R, Church J, Giardiello F, Hampel H, Burt R . ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015; 110(2):223-62. PMC: 4695986. DOI: 10.1038/ajg.2014.435. View

Win A, Jenkins M, Dowty J, Antoniou A, Lee A, Giles G . Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2016; 26(3):404-412. PMC: 5336409. DOI: 10.1158/1055-9965.EPI-16-0693. View

Meyer L, Broaddus R, Lu K . Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2008; 16(1):14-22. PMC: 3693757. DOI: 10.1177/107327480901600103. View

Rostgaard K . Methods for stratification of person-time and events - a prerequisite for Poisson regression and SIR estimation. Epidemiol Perspect Innov. 2008; 5:7. PMC: 2615420. DOI: 10.1186/1742-5573-5-7. View

Hampel H, Stephens J, Pukkala E, Sankila R, Aaltonen L, Mecklin J . Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005; 129(2):415-21. DOI: 10.1016/j.gastro.2005.05.011. View

Therkildsen C, Ladelund S, Rambech E, Persson A, Petersen A, Nilbert M . Glioblastomas, astrocytomas and oligodendrogliomas linked to Lynch syndrome. Eur J Neurol. 2015; 22(4):717-24. DOI: 10.1111/ene.12647. View

10.

Therkildsen C, Joost P, Lindberg L, Ladelund S, Smith-Hansen L, Nilbert M . Renal cell cancer linked to Lynch syndrome: Increased incidence and loss of mismatch repair protein expression. Int J Urol. 2016; 23(6):528-9. DOI: 10.1111/iju.13094. View

11.

Watson P, Vasen H, Mecklin J, Bernstein I, Aarnio M, Jarvinen H . The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008; 123(2):444-449. PMC: 2627772. DOI: 10.1002/ijc.23508. View

12.

Giardiello F, Allen J, Axilbund J, Boland C, Burke C, Burt R . Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 2014; 109(8):1159-79. DOI: 10.1038/ajg.2014.186. View

13.

Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W . Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 2012; 30(35):4409-15. DOI: 10.1200/JCO.2012.43.2278. View

14.

Pylvanainen K, Lehtinen T, Kellokumpu I, Jarvinen H, Mecklin J . Causes of death of mutation carriers in Finnish Lynch syndrome families. Fam Cancer. 2012; 11(3):467-71. DOI: 10.1007/s10689-012-9537-3. View

15.

Jensen U, Sunde L, Timshel S, Halvarsson B, Nissen A, Bernstein I . Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat. 2009; 120(3):777-82. DOI: 10.1007/s10549-009-0449-3. View

16.

Dominguez-Valentin M, Joost P, Therkildsen C, Jonsson M, Rambech E, Nilbert M . Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol. 2016; 16:15. PMC: 4806412. DOI: 10.1186/s12894-016-0130-1. View

17.

van Duijnhoven F, Botma A, Winkels R, Nagengast F, Vasen H, Kampman E . Do lifestyle factors influence colorectal cancer risk in Lynch syndrome?. Fam Cancer. 2013; 12(2):285-93. DOI: 10.1007/s10689-013-9645-8. View

18.

Joost P, Therkildsen C, Dominguez-Valentin M, Jonsson M, Nilbert M . Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology. 2015; 86(6):1212-7. DOI: 10.1016/j.urology.2015.08.018. View

19.

Raymond V, Mukherjee B, Wang F, Huang S, Stoffel E, Kastrinos F . Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol. 2013; 31(14):1713-8. PMC: 3641694. DOI: 10.1200/JCO.2012.44.1238. View

20.

Aarnio M, Saily M, Juhola M, Gylling A, Peltomaki P, Jarvinen H . Uroepithelial and kidney carcinoma in Lynch syndrome. Fam Cancer. 2012; 11(3):395-401. DOI: 10.1007/s10689-012-9526-6. View